Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oblimersen + docetaxel
- Development stage
- Unknown
- Lead developer
- Genta
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
**Oblimersen + docetaxel** is a combination regimen consisting of oblimersen, a phosphorothioate antisense oligonucleotide that specifically targets and downregulates Bcl-2 mRNA, and docetaxel, a microtubule-stabilizing taxane chemotherapeutic. Oblimersen reduces expression of the anti-apoptotic protein Bcl-2, thereby sensitizing tumor cells to apoptosis induced by cytotoxic agents such as docetaxel. This combination has been evaluated primarily in hormone-refractory/castration-resistant prostate cancer and in neoadjuvant systemic therapy for breast cancer, with the goal of enhancing tumor cell death and improving antitumor efficacy by combining Bcl-2 downregulation with microtubule inhibition[1][2][3][5].
- Other names
- oblimersen sodiumBcl-2 antisense oligonucleotideBcl2 antisense oligonucleotideBcl 2 antisense oligonucleotideG3139 + docetaxel
02
Targets
BCL-2 (BCL-2 family)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on oblimersen + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oblimersen + docetaxel.